Ibrahim and colleagues conducted more in-depth research and made similar findings: the use of PGE2 antagonists alone, and the combination with BCG and indomethacin, can selectively enhance the chemoattractant factor CXCL10 for CTLs, achieving immune reprogramming in BLCA [14]. This evidence concerns the gene CXCL10 and bladder transitional cell carcinoma.